title: Treatment with mirtazapine and venlafaxine increases noradrenaline excretion in depressed patients.
authors: Olivera
authors: O
authors: Lecei
authors: Florian
authors: F
authors: Lederbogen
authors: Wolfgang
authors: W
authors: Gronau
authors: Barbara
authors: B
authors: Scharnholz
authors: Johannes
authors: J
authors: Terhardt
authors: Claudia
authors: C
authors: Schilling
authors: Maria
authors: M
authors: Gilles
authors: Daniel
authors: D
authors: Kopf
authors: Heinz Juergen
authors: HJ
authors: Roth
authors: Bettina
authors: B
authors: Weber-Hamann
authors: Michael
authors: M
authors: Deuschle
mesh_terms: D000328:Adult; D018687:Antidepressive Agents, Second-Generation / Q000627:therapeutic use; D000929:Antidepressive Agents, Tricyclic / Q000627:therapeutic use; D003511:Cyclohexanols / Q000627:therapeutic use*; D003865:Major Depressive Disorder / Q000188:drug therapy* / Q000652:urine*; D005260:Female; D006801:Humans; D008297:Male; D008803:Mianserin / Q000031:analogs & derivatives* / Q000627:therapeutic use; D008875:Middle Aged; D000078785:Mirtazapine; D009638:Norepinephrine / Q000652:urine*; D000069470:Venlafaxine Hydrochloride
chemical_list: D018687:Antidepressive Agents, Second-Generation; D000929:Antidepressive Agents, Tricyclic; D003511:Cyclohexanols; D008803:Mianserin; D000069470:Venlafaxine Hydrochloride; D000078785:Mirtazapine; D009638:Norepinephrine